Top-News
Biotechnologie USA

Alnylam Pharmaceuticals Inc Aktie

Aktie
WKN:  A0CBCK ISIN:  US02043Q1076 US-Symbol:  ALNY
225,50 €
-6,70 €
-2,89%
11:02:37 Uhr
Depot/Watchlist
Aktienanzahl *
128,38 Mio.
Marktkapitalisierung *
29,83 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 21.08.2024
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,42: MK5DGN
Werbung

Alnylam Pharmaceuticals Inc News

12.12.24 - wallstreetONLINE Redaktion
Morgen ist Showtime: Nasdaq 100: Palantir hofft, MicroStrategy zittert, Super Micro droht Rauswurf!
Am Freitag ist Showtime, denn der Nasdaq 100 wird neu sortiert. Palantir und MicroStrategy hoffen auf eine Aufnahme, während Player wie Super Micro zittern. Die Index-...
30.08.24 - LYNX Analysen
Alnylam Pharmaceuticals überzeugt – aktueller Favorit der Anleger
Das US-​amerikanische Biotechnologieunternehmen ist ein neuer Stern in der Biotech-​Branche. Die Alnylam-​Aktie machte in den letzten beiden Monaten einen Kurssprung von ...
26.06.24 - Der Aktionär
Aktienreport‑Tipp Alnylam nicht zu bremsen – Bayer überholt
24.06.24 - Der Aktionär
Aktienreport‑Tipp Alnylam explodiert knapp 40 Prozent: Das ist der Grund
30.04.24 - PR Newswire
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-​Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional ...
30.04.24 - PR Newswire
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-​Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional ...
11.03.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
03.03.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
03.11.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
25.10.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
17.10.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
09.03.23 - PR Newswire
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-​Regional Partnership to Commercialize RNAi Therapeutics PR Newswire
09.03.23 - PR Newswire
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-​Regional Partnership to Commercialize RNAi Therapeutics PR Newswire
15.09.22 - PR Newswire
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers PR Newswire
03.08.22 - PR Newswire
Thinking about trading options or stock in Apple, Alnylam Pharmaceuticals, Atlas Air Worldwide, Alteryx, or Chevron?
Thinking about trading options or stock in Apple, Alnylam Pharmaceuticals, Atlas Air Worldwide, Alteryx, or Chevron? PR Newswire
09.12.21 - PR Newswire
Direxion Launches mRNA ETF (MSGR)
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire
28.09.21 - PR Newswire
ONPATTRO® (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR)
ONPATTRO® (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR) Canada NewsWire
19.07.21 - PR Newswire
Thinking about trading options or stock in Alnylam Pharmaceuticals, Tesla, Cintas, GameStop, or Microsoft?
Thinking about trading options or stock in Alnylam Pharmaceuticals, Tesla, Cintas, GameStop, or Microsoft? PR Newswire
08.12.20 - EQS
CENTOGENE und Alnylam Pharmaceuticals schließen Vereinbarung zum Start eines neuen klinischen Programms zur Revolutionierung der Diagnose der Erbkrankheit Transthyretin assoziierte Amyloidose ('ATTRv')
DGAP-News: Centogene NV / Schlagwort(e): Vereinbarung CENTOGENE und Alnylam Pharmaceuticals schließen Vereinbarung zum Start eines neuen klinischen Programms zur ...
03.12.20 - PR Newswire
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary ...

Newssuche

Videos

newspaper
30.04.25 +3,37%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »